TY - JOUR
T1 - Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection
AU - Zugna, Daniela
AU - Geskus, Ronald B
AU - De Stavola, Bianca
AU - Rosinska, Magdalena
AU - Bartmeyer, Barbara
AU - Boufassa, Faroudy
AU - Chaix, Marie-Laure
AU - Babiker, Abdel
AU - Porter, Kholoud
AU - CASCADE collaboration in EuroCoord
A2 - Lundgren, Jens D.
PY - 2012
Y1 - 2012
N2 - BACKGROUND: Estimates of treatment failure, change and interruption are lacking for individuals treated in early HIV infection.METHODS: Using CASCADE data, we compared the effect of treatment in early infection (within 12 months of seroconversion) with that seen in chronic infection on risk of virological failure, change and interruption. Failure was defined as two subsequent measures of HIV RNA>1,000 copies/ml following suppression (<500 copies/ml), or >500 copies/ml 6 months following initiation. Treatment change and interruption were defined as modification or interruption lasting >1 week. In multivariable competing risks proportional subdistribution hazards models, we adjusted for combination antiretroviral therapy (cART) class, sex, risk group, age, CD4(+) T-cell count, HIV RNA and calendar period at treatment initiation.RESULTS: Of 1,627 individuals initiating cART early (median 1.8 months from seroconversion), 159, 395 and 692 failed, changed and interrupted therapy, respectively. For 2,710 individuals initiating cART in chronic infection (median 35.9 months from seroconversion), the corresponding values were 266, 569 and 597. Adjusted hazard ratios (HRs; 95% CIs) for treatment failure and change were similar between the two treatment groups (0.93 [0.72, 1.20] and 1.06 [0.91, 1.24], respectively). There was an increasing trend in rates of interruption over calendar time for those treated early, and a decreasing trend for those starting treatment in chronic infection. Consequently, compared with chronic infection, treatment interruption was similar for early starters in the early cART period, but the relative hazard increased over calendar time (1.54 [1.33, 1.79] in 2000).CONCLUSIONS: Individuals initiating treatment in early HIV infection are more likely to interrupt treatment than those initiating later. However, rates of failure and treatment change were similar between the two groups.
AB - BACKGROUND: Estimates of treatment failure, change and interruption are lacking for individuals treated in early HIV infection.METHODS: Using CASCADE data, we compared the effect of treatment in early infection (within 12 months of seroconversion) with that seen in chronic infection on risk of virological failure, change and interruption. Failure was defined as two subsequent measures of HIV RNA>1,000 copies/ml following suppression (<500 copies/ml), or >500 copies/ml 6 months following initiation. Treatment change and interruption were defined as modification or interruption lasting >1 week. In multivariable competing risks proportional subdistribution hazards models, we adjusted for combination antiretroviral therapy (cART) class, sex, risk group, age, CD4(+) T-cell count, HIV RNA and calendar period at treatment initiation.RESULTS: Of 1,627 individuals initiating cART early (median 1.8 months from seroconversion), 159, 395 and 692 failed, changed and interrupted therapy, respectively. For 2,710 individuals initiating cART in chronic infection (median 35.9 months from seroconversion), the corresponding values were 266, 569 and 597. Adjusted hazard ratios (HRs; 95% CIs) for treatment failure and change were similar between the two treatment groups (0.93 [0.72, 1.20] and 1.06 [0.91, 1.24], respectively). There was an increasing trend in rates of interruption over calendar time for those treated early, and a decreasing trend for those starting treatment in chronic infection. Consequently, compared with chronic infection, treatment interruption was similar for early starters in the early cART period, but the relative hazard increased over calendar time (1.54 [1.33, 1.79] in 2000).CONCLUSIONS: Individuals initiating treatment in early HIV infection are more likely to interrupt treatment than those initiating later. However, rates of failure and treatment change were similar between the two groups.
KW - Adolescent
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Anti-HIV Agents/administration & dosage
KW - CD4 Lymphocyte Count
KW - Chronic Disease/drug therapy
KW - Confidence Intervals
KW - Female
KW - Follow-Up Studies
KW - HIV/pathogenicity
KW - HIV Infections/drug therapy
KW - HIV Seropositivity/drug therapy
KW - Humans
KW - Male
KW - Middle Aged
KW - Proportional Hazards Models
KW - RNA, Viral/analysis
KW - Time Factors
KW - Treatment Failure
KW - Young Adult
U2 - 10.3851/IMP2312
DO - 10.3851/IMP2312
M3 - Journal article
C2 - 22910338
SN - 1359-6535
VL - 17
SP - 1039
EP - 1048
JO - Antiviral Therapy
JF - Antiviral Therapy
IS - 6
ER -